Corneal Confocal Microscopy: a Surrogate Endpoint for Neurodegeneration in Clinical Trials


POSTPONED TO A LATER DATE TO BE ANNOUNCED

Optical Coherence Tomography in Multiple Sclerosis


Quantitative central nervous system-based imaging methodologies are increasingly widespread tools that can monitor and predict disease severity for a variety of neurological disorders, including multiple sclerosis (MS). While neuroimaging modalities (e.g. structural MRI) remain the most commonly applied CNS-based imaging approaches, many previous studies have suggested that the eye may serve as a “window into the brainin MS and that additional imaging tools of retinal structure via optical coherence tomography (OCT) or other visual outcome measures could provide a unique set of advantages and insight into ongoing brain processes in MS. This talk will discuss describe the use of OCT in MS and will characterize its development into a highly reproducible and validated outcome measure. In MS, OCT measures correlate with clinical and imaging-based outcomes. For example, studies find that the ganglion cell-inner plexiform layer (GCIP) correlates strongly with gray matter atrophy and disability accrual; other OCT-derived measures are also associated with progressive visual function loss and risk of disability progression. In addition to its role as a sensitive biomarker for disease progression, OCT may be a tool for discovery biology in MS – we will discuss emerging evidence describing this potential. Lastly, we will discuss results for other promising OCT-related technologies in MS including OCT-angiography and how it may monitor aspects of MS severity.